Skip to main content

Table 1 Inquiries and approvals for Ranibizumab according to the type of retinal disease, age and gender (source: authors’ analysis of data from Clalit Mushlams’ cohort of members funding applications, March 1, 2012 to December 31, 2015]

From: Cost containment by peer prior authorization program for second line treatment in patients with retinal disease

  AMD Other CNV RVO DME Other Complex Dx Total
n = 3445 n = 16 n = 467 n = 1365 n = 25 n = 324 n = 5642
Age - years, mean ± SD 79.7 ± 9.02 71.6 ± 11.02 61.1 ± 15.61 66.7 ± 9.12 71.1 ± 12.29 70.0 ± 7.73 75.3 ± 11.13
Gender-female, n(%) 1919 (56%) 8 (50%) 234 (50%) 560 (41%) 12 (48%) 134 (41%) 2867 (51%)
Total Inquiries, n 11,107 24 1054 3053 31 1509 16,778
Approved inquiries, n(%) 8700 (78%) 19 (79%) 900 (85%) 2575 (84%) 0 (0%) 1084 (72%) 13,278 (79%)
  1. SD standard deviation, n number of eyes, Age Age at examination, AMD neovascular age related macular degeneration, CNV choroidal neovascularization, RVO retinal vein occlusion, DME diabetic macular edema, Dx diagnosis